These findings suggest that in oligodendroglial tumors TP53 mutations are more likely to be later events where they may function to mediate progression or resistance to therapy, while in astrocytic and mixed lineage tumors TP53 and ATRX lesions are often early genetic events along with IDH1 mutations. This evidence concerns the gene ATRX and oligodendroglial tumor.